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276Objective: The bicuspid aorta is thought to have a higher risk of progressive dilation after aortic valve replace-
ment with a subsequently increased risk of adverse aortic events. Our aim was to compare the risk of late aortic
events after isolated aortic valve replacement surgery for bicuspid versus tricuspid aortic valve stenosis with
concomitant mild to moderate dilatation of the proximal aorta.
Methods:A total of 325 consecutive patients (60%males; mean age, 59.5 10 years) with aortic valve stenosis
and concomitant ascending aortic dilatation of 40 to 50 mm underwent isolated aortic valve replacement from
1995 through 2000. A total of 153 patients (47%) were diagnosed with bicuspid aortic valve stenosis (bicuspid
aortic valve group), whereas the remaining 172 patients (53%) had tricuspid aortic valve stenosis (tricuspid aor-
tic valve group). Follow-up (3566 patient-years) was 100% complete. Adverse aortic events were defined as the
need for proximal aortic surgery or the occurrence of aortic dissection/rupture or sudden death during follow-up.
Results:Overall survival was 78 4% in the bicuspid aortic valve group versus 55 6% in the tricuspid aortic
valve group (P ¼ .006) at 15 years postoperatively, but age-adjusted survival was not significantly different be-
tween groups (P¼ .4). A total of 5 patients (3%) in the bicuspid aortic valve group versus 9 patients (5%) in the
tricuspid aortic valve group underwent proximal aortic surgery during follow-up. Aortic dissection occurred in 3
patients in the tricuspid aortic valve group and in no bicuspid aortic valve patients. Fifteen-year freedom from
adverse aortic events was 93  3% in the bicuspid aortic valve group versus 82  6% in the tricuspid aortic
valve group (P ¼ .2).
Conclusions: Patients with bicuspid and tricuspid aortic valve stenosis with concomitant mild to moderate
ascending aortic dilatation are at comparably low risk of adverse aortic events 15 years after isolated aortic valve
replacement. (J Thorac Cardiovasc Surg 2014;147:276-82)The bicuspid aorta has been proposed to dilate progres-
sively after isolated aortic valve replacement (AVR) at an
accelerated rate, a process that is followed by an increased
risk of adverse aortic events.1,2 The explanation for this
phenomenon has been based predominantly on the genetic
hypothesis of aortopathy in bicuspid aortic valve (BAV)
disease.2-4 The widespread popularity of the genetic
theory, which considers BAV aortopathy a congenital
disorder of vascular connective tissue, has led to more
aggressive treatment recommendations of the proximal
aorta in such patients, approaching aortic management
recommendations of Marfan syndrome.5,6 However, such
an aggressive surgical treatment strategy of BAV
aortopathy has been questioned by some investigators.7
Recent in vitro and in vivo studies brought major
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The Journal of Thoracic and Cardiovascular Surgprovided hemodynamic insight into the different clinical
forms of BAV disease.10,11 In the face of these recent
important findings, the reevaluation of clinical data on
bicuspid aortopathy is appropriate. Considering the
heterogeneity of BAV disease,12,13 clinical research
should also take into account the distinct homogeneous
patient subgroups. We therefore restricted our analysis to
1 clinically relevant subgroup of BAV patients—those
with bicuspid valve stenosis and mild to moderate
dilatation of the proximal aorta who underwent isolated
AVR surgery.
Our aim was to compare the risk of late aortic events after
isolated AVR for bicuspid versus tricuspid aortic valve ste-
nosis with concomitant mild to moderate dilatation of the
proximal aorta using long-term follow-up.
METHODS
We reviewed our institutional valve surgery database to identify all pa-
tients who underwent isolated AVR for predominant/pure aortic valve ste-
nosis with concomitant ascending aortic dilatation of 40 to 50 mm between
January 1995 and January 2001 at the Central Hospital Bad Berka. A total
of 1095 patients underwent an isolated AVR surgery during the study pe-
riod (255 BAV patients and 840 tricuspid aortic valve [TAV] patients). Con-
comitant replacement of the proximal aorta was required in 110 patients
with dilatation of the ascending aorta>50 mm (53 BAV patients and 57
TAV patients). Patients with mixed aortic valve lesions were included
only if valve stenosis was the predominant lesion (ie, patients with a severe
stenosis and mild to moderate aortic valve insufficiency were assigned toery c January 2014
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
BAV ¼ bicuspid aortic valve
TAV ¼ tricuspid aortic valve
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were not included to have an adequate long-term follow-up (ie, at least
10 years post-AVR).
A total of 325 consecutive patients with predominant/pure aortic valve
stenosis and concomitant ascending aortic dilatation of 40 to 50 mm under-
went isolated AVR surgery during the study period. Patients with bicuspid
aortic valve stenosis (BAV group, n ¼ 153) were identified and compared
with those with tricuspid valve stenosis (TAV group, n ¼ 172). The valve
was identified as bicuspid or tricuspid based principally on intraoperative
direct inspection (discussed later). Study approval was obtained from the
local ethics committee. Individual patient consent was waived.
The primary end point of our study was freedom from late adverse
aortic events in the BAV group versus the TAV group. Adverse aortic
events were defined as the need for proximal aortic surgery or the occur-
rence of aortic dissection/rupture or sudden cardiac death during long-
term follow-up.
Definitions and Measurements
The morphology and function of the aortic valve was assessed by pre-
operative echocardiography in all patients. The BAV was suspected if
2-dimensional short-axis imaging of the aortic valve demonstrated the
existence of only 2 commissures delimiting 2 aortic valve cusps. The fi-
nal decision regarding the bicuspidality or tricuspidality of the aortic
valve, however, was made based on the intraoperative description of
valve morphology by the surgeon. Aortic valve stenosis was defined
using the uniform and validated Doppler-based echocardiographic
measurements.
The diameter of the proximal aorta was measured preoperatively by
means of transthoracic 2-dimensional echocardiography and routine aortic
angiography during cardiac catheterization. Multiple echocardiographic
measurements of the maximal diameter of the ascending aorta were per-
formed in systole using a parasternal long-axis view. Moreover, proximal
aortic dimensions were measured at multiple sites on aortic angiography
and the maximal aortic diameter was recorded. A proximal aortic diame-
ter of 40 mm was our cutoff value for defining dilatation of the aorta. In
the current study, we used the maximal diameter of the proximal aorta,
which was the supracoronary portion in the vast majority of our study
population. Therefore, this measure is restricted mostly to the ascending
portion of the proximal aorta. All patients with a dilated proximal aorta,
as diagnosed in these screening examinations, underwent subsequent pre-
operative computed tomography or magnetic resonance angiography of
the thoracic aorta. Moreover, the maximal diameter of the proximal aorta
was measured routinely intraoperatively (ie, using a caliper) before going
on pump. The proximal aorta was defined as normal size only if all 3 mea-
surements (ie, echocardiography, aortic angiography, and intraoperative
measurement) described the aortic diameter consistently of<40 mm. If
a proximal aortic aneurysm>50 mm in maximal diameter was observed,
then simultaneous aortic surgery was performed. In all remaining patients
with a proximal aortic diameter of 40 to 50 mm, isolated AVR was
performed.
Arterial hypertension was defined as a systemic blood pressure of>140/
90 mm Hg recorded at multiple measurements and/or evidence of long-
standing systemic hypertension treated by medication before AVR.
Systemic hypertension was treated by medication in 80% of the study
patients.The Journal of Thoracic and CaStudy Population
Demographics and intraoperative variables of both study groups are dis-
played in Table 1. Patients in the BAV groupwere significantly younger and
less symptomatic compared with the TAV group. Moreover, there was
a clear predominance of male patients in the BAV group. More important,
no significant difference in the diameter of ascending aorta was found
between the study groups at the time of AVR surgery.
All 325 patients underwent conventional isolated AVR surgery through
amedian sternotomy or partial upper L-ministernotomy using standard car-
diopulmonary bypass and moderate systemic hypothermia. Intraoperative
management was uniform without any major changes over time. The intra-
operative variables of both study groups are presented in Table 2. Aortic
crossclamp time and cardiopulmonary bypass time tended to be longer in
the BAV group. Moreover, a mechanical valve prosthesis was implanted
more frequently in the BAV group compared with the TAV group. There
was a tendency toward an implantation of a larger prosthesis size in the
BAV group.
Follow-up
Our follow-up protocol consisted of a telephone interview with the pa-
tients, their family members, and/or the patients’ general practitioners. All
imaging data obtained during the postoperative course (echocardiography
reports, computed tomographic scans/magnetic resonance angiographic
images) were obtained from patients’ cardiologists or general practitioners
and were entered into our database. There was no standard follow-up pro-
tocol for aortic imaging in the current study. Surgical notes were obtained
on all patients who underwent redo cardiac surgery. A total of 62 patients
(19%) were treated for noncardiac reasons in our hospital during the post-
operative course and their medical records were obtained for follow-up. All
medical records of patients who died in external hospitals were forwarded
on request to our hospital. In all cases of out-of-hospital death, we aimed to
confirm or exclude sudden cardiac death. In a total of 35 patients (11%) in
whom no contact details were available, a telephone book-based search
was performed.
Statistical Analysis
Standard definitions were used for patient variables and outcomes. Cat-
egorical variables are expressed as percentages, and continuous variables
are expressed as mean standard deviation with range. All statistical anal-
yses were performed with the IBM SPSS 19.0 software (IBM Corp, New
York, NY). Survival analysis was performed according to the methods of
Kaplan-Meier, and statistical differences were analyzed using the log-
rank test. Age-adjusted survival was compared using the log-rank test. A
multivariable analysis (ie, Cox regression) of risk factors for adverse aortic
events was performed. All variables were screened initially in the univari-
ate model and were considered for clinical relevance before including them
in the multivariate model.RESULTS
Perioperative Results
The in-hospital outcomes are summarized in Table 3.
In-hospital mortality was comparable between the study
groups (ie, 0.7% in the BAV group vs 2.3% in the TAV
group, P ¼ .3). Two patients (1 patient in the BAV group
and 1 patient in the TAV group) died suddenly on the sur-
gical ward, most probably as a result of a fatal arrhythmia.
An autopsy examination was performed in both cases
without evidence of aortic dissection or rupture. One pa-
tient in the TAV group died of major stroke 3 days after
AVR surgery. Two additional patients in the TAV grouprdiovascular Surgery c Volume 147, Number 1 277
TABLE 1. Demographics and intraoperative variables
Variable
BAV group
(n ¼ 153)
TAV group
(n ¼ 172)
P
value
Mean age, y;
mean  SD (range)
54  11 (22-76) 64  7 (42-75) <.001
Male, n (%) 112 (73) 82 (48) <.001
BSA, m2;
mean  SD (range)
1.7  0.2 (1.3-2.2) 1.7  0.2 (1.4-2.3) .7
NYHA class III/IV,
n (%)
77 (50) 107 (62) .03
Ascending aorta, mm;
mean  SD (range)*
46  3 (40-50) 45  4 (40-50) .5
Ascending aorta
45 mm, n (%)*
60 (39) 70 (40) .9
Arterial hypertension,
n (%)
74 (48) 98 (57) .2
Diabetes, n (%) 17 (11) 27 (16) .6
History of smoking,
n (%)
55 (36) 69 (40) .6
Peripheral arterial
disease, n (%)
4 (3) 5 (3) .9
COLD, n (%) 14 (9) 15 (9) .9
Urgent/emergency
surgery, n (%)
19 (12) 27 (16) .4
CPB time, min;
mean  SD (range)
73  21 (45-190) 69  16 (47-141) .06
Crossclamp time, min;
mean  SD (range)
37  10 (31-71) 35  8 (30-60) .1
Mechanical prosthesis 142 (93) 146 (85) .05
Mean prosthesis
size, mm;
mean  SD (range)
25  2 (21-29) 24  2 (21-29) .07
BAV, Bicuspid aortic valve; TAV, tricuspid aortic valve; SD, standard deviation; BSA,
body surface area; NYHA, New York Heart Association; COLD, chronic obstructive
lung disease; CPB, cardiopulmonary bypass. *As measured by preoperative com-
puted tomography/magnetic resonance angiography.
TABLE 3. Causes of late deaths
Cause of death
BAV group,
n (n ¼ 152)
TAV group,
n (n ¼ 168)
Cardiac death 15 (57%) 21 (45%)
Congestive heart failure 2 3
Myocardial infarction 2 1
Aortic dissection 0 2
Arrhythmia 0 1
Valve related
Stroke 4 4
Hemorrhage 3 2
Thrombosis 0 1
Endocarditis 1 1
Sudden death 3 6
Noncardiac death 12 (43%) 23 (49%)
Malignancy 4 14
Chronic end-stage disease 3 6
Infection 3 3
Trauma 1 0
Suicide 1 0
Unknown 0 3 (6%)
Total death 27 47
BAV, Bicuspid aortic valve; TAV, tricuspid aortic valve.
Acquired Cardiovascular Disease Girdauskas et al
A
C
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course (ie, resulting from sepsis-induced multiorgan fail-
ure in 1 patient and multiple bleeding complications in
the other). None of the in-hospital deaths were aortic
related.TABLE 2. In-hospital outcomes
Variable
BAV group
(n ¼ 153)
TAV group
(n ¼ 172)
P
value
Low-cardiac output syndrome,
n (%)
4 (3) 8 (5) .8
Reoperation for bleeding, n (%) 7 (5) 17 (10) .1
Dialysis-dependant renal
failure, n (%)
1 (1) 2 (1) .9
Stroke, n (%) 2 (1) 4 (2) .5
Tracheotomy, n (%) 2 (1) 5 (3) .8
Hospital stay, days,
mean  SD (range)
14  7 (8-59) 15  8 (2-74) .3
Hospital mortality, n (%) 1 (0.7) 4 (2.3) .3
BAV, Bicuspid aortic valve; TAV, tricuspid aortic valve; SD, standard deviation.
278 The Journal of Thoracic and Cardiovascular SurgFollow-up Results
Follow-up data (a total of 3566 patient-years) were ob-
tained on all 320 hospital survivors (100%). The mean
length of follow was of comparable duration between
groups—11.5  3.2 years in the BAV group versus 10.5
 6 years in the TAV group (P ¼ .1).
A total of 27 patients (18%) in the BAV group versus 47
patients (28%) in the TAV group died during follow-up.
The causes of late deaths in both groups are summarized
in Table 3. The causes of late deaths were mostly cardiac re-
lated (57%) in the BAV group, and 3 of these patients died
suddenly. Cardiac and noncardiac causes were almost
equally distributed in the TAV group, and the largest propor-
tion of TAV patients died of malignancies (n¼ 14 patients).
More important, 6 patients in the TAV group and 3 patients
in the BAV group experienced sudden cardiac death. More-
over, 2 patients in the TAV group died of chronic type A
aortic dissection after redo surgery.
The overall survival after the 15-year follow-up was 78
4% in the BAV group versus 55  6% in the TAV group
(log rank, P ¼ .006; Figure 1). We also performed an
age-adjusted survival analysis because of the markedly dif-
ferent ages of the 2 groups at baseline. We failed to find
a significant difference in age-adjusted survival (P ¼ .4).Proximal Aortic Surgery
Proximal aortic surgery was required in 5 patients (3%) in
the BAV group versus 9 patients (5%) in the TAV group.
The prevalence of proximal aortic surgery was 2.8 of 1000
patient-years in the BAV group versus 5.0 of 1000
patient-years in the TAV group. The mean length of timeery c January 2014
 0 5 10 15 
BAV 153 133 113 22 
TAV 172 121 103 21 
FIGURE 1. Overall survival (Kaplan-Meier). BAV, Bicuspid aortic valve;
TAV, tricuspid aortic valve.
 0 5 10 15 
BAV 153 133 113 22 
TAV 172 120 102 20 
FIGURE 2. Freedom from adverse aortic events (Kaplan-Meier).
BAV, Bicuspid aortic valve; TAV, tricuspid aortic valve.
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between the groups (ie, 8 2 years in the BAV group vs 9 
4 years in the TAVgroup,P¼ .3). The freedom from proximal
aortic surgery at 15 years post-AVRwas 94 3% in the BAV
group versus 89 5% in the TAV group (log rank, P ¼ .2).
The most common indication for proximal aortic surgery
was progression of the ascending aortic aneurysm.More im-
portant, 3 patients in the TAV group required urgent/emer-
gency aortic surgery for type A aortic dissection (ie, 2
chronic and 1 acute aortic dissection), whereas no cases of
aortic dissection were observed in the BAV group. The
mean diameter of the proximal aorta at the time of aortic sur-
gery was 53 2mm in the BAVgroup versus 67 15mm in
the TAV group (P ¼ .005). This difference was predomi-
nantly a result of themarkedly dilated diameters of the prox-
imal aorta in 3 patients with aortic dissections in the TAV
group (ie, diameters of the proximal aorta of 110 mm, 75
mm, and 80 mm, respectively). The surgical treatment strat-
egy of the proximal aorta was comparable between the
groups; a composite graft aortic root replacement was per-
formed in the majority of patients (ie, 60% in both groups).
The remaining reoperated patients underwent supracoro-
nary replacement of the ascending aorta and replacement
of the mechanical valve with a bioprosthesis.
Additional indications for redo surgery without interven-
tion on the aorta were observed in 2 patients in the BAV
group and in 1 patient in the TAV group. One such patientThe Journal of Thoracic and Cain the BAV group had multiple bleeding events resulting
from oral anticoagulation and required a biological prosthe-
sis. The second patient had a significant paravalvular leak
with accompanying hemolysis, requiring redo AVR. One
patient in the TAV group underwent subsequent coronary
artery bypass grafting because of symptomatic 3-vessel cor-
onary artery disease.
All 5 patients in the BAV group survived the redo surgery
uneventfully, whereas 2 patients in the TAV group (with
type A aortic dissection) expired postoperatively. One pa-
tient died of low cardiac output on the second postoperative
day. The second patient experienced a severe systemic in-
flammatory response syndrome immediately after surgery
and died of progressive multiorgan failure within the first
6 hours after operation.
The primary end point variable (ie, adverse aortic events)
occurred in 8 of 152 patients (5%) in the BAV group versus
15 of 168 patients (9%) in the TAV group. The freedom
from adverse aortic events at 15 years post-AVR was 93
 3% in the BAV group versus 82  6% in the TAV group
(log rank, P ¼ .2; Figure 2).
A Cox regression analysis was performed to identify in-
dependent risk factors of adverse aortic events. A total of 3
variables were included in the multivariate model—namely,
the presence of BAV, proximal aortic diameter at the time of
AVR surgery (as a continuous variable), and arterialrdiovascular Surgery c Volume 147, Number 1 279
TABLE 4. Risk factors of adverse aortic events (Cox regression)
Variable Hazard ratio 95% CI P value
Hypertension 4.8 1.2-22.4 .04
Ascending aorta, mm* 1.3 0.3-3.9 .8
BAV disease 0.8 0.4-2.7 .8
CI, Confidence interval; BAV, bicuspid aortic valve. *In the range of 40 to 50 mm, as
defined by preoperative computed tomography/magnetic resonance angiography.
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as a significant predictor of adverse aortic events (hazard
ratio, 4.8; 95% confidence interval, 1.2-22.4).DISCUSSION
The treatment of dilated proximal aorta in patients with
BAV disease is controversial.14 The increased risk of
acute aortic complications has been proposed in BAV
patients, including a 9-fold higher prevalence of aortic dissec-
tion in some series.15,16 Most of these data come from
large necropsy studies, however, which may inherently
overestimate the prevalence of aortic complications in the
BAV population. Larger dimensions of the proximal aorta in
persons with BAV versus TAV have been presumed to result
in an increased risk of acute aortic complications during
follow-up.However, direct evidenceof an increased risk of ad-
verse aortic events in such patients is lacking. Observed dila-
tationof the proximal aortawithout echocardiographic criteria
of relevant BAV stenosis or insufficiency (ie, aortic dilatation
out of proportion to coexistent valvular lesion) has also served
as a strong argument for the congenital origin of BAVaortop-
athy,17 further supporting the argument for a more aggressive
approach to aortic management in such patients.
Since the pioneering contribution by Robicsek and col-
leagues,18 an ever-increasing amount of clinical and basic
science studies have focused on the function of ‘‘clinically
normal’’ BAV and the patterns of transvalvular flow.8-11
These studies showed consistently eccentric turbulent
transvalvular flow in the setting of the clinically normal
BAV.8,9 Moreover, a strong correlation has been
demonstrated between the specific transvalvular flow
pattern and the segmental dilatation of the proximal aorta
in BAV disease.10,11 Another important study compared
biomolecular changes in the ascending aorta of patients
with bicuspid versus tricuspid aortic valve stenosis at the
time of AVR surgery.19 Bicuspid aortic valve stenosis was
associated with a more severe medial remodeling of the as-
cending aorta, which occurred earlier during the aneurysm
course, and it had an asymmetric spatial pattern compared
with that observed with TAV stenosis. These findings con-
firm once again the more severe transvalvular flow distur-
bances in BAV patients and add more support to the
hemodynamic theory, as opposed to the genetic theory, of
BAV-associated aortopathy.
Based on these important recent in vitro and in vivo find-
ings, we addressed the issue of pathogenesis of BAV280 The Journal of Thoracic and Cardiovascular Surgaortopathy in a systematic review of the literature.20 One
of the key questions in this review was the natural course
of the proximal aorta in BAV patients after isolated AVR.
The cumulative analysis of results from 3 follow-up stud-
ies2,21,22 showed that about 5 to 30% of BAV patients may
experience late aortic events after isolated AVR surgery.
However, the majority of these events were replacement of
the aorta during planned, elective redo AVR surgery. The
incidence of documented catastrophic acute aortic events
(ie, aortic dissection or rupture) was considerably low—
only 6 events in 5288 cumulative patient-years. Because of
the high variability in the prevalence of aortic events among
these studies (ie, heterogeneous characteristics of the in-
cluded patients), no definite conclusions could be drawn.
Recently, a very low risk of late aortic events (ie, 1.9%
risk of cumulative events after median follow-up of 12
years) has been demonstrated in a BAV cohort after isolated
AVR surgery in a large-scale follow-up study from theMayo
Clinic.23 Our current study confirms this considerably low
risk of adverse aortic events in the BAV group (ie, 93% free-
dom from adverse aortic events at 15 years post-AVR).
One important difference betweenour study and that of the
Mayo Clinic, however, is that our BAV group consisted of
a homogeneous (and most common) phenotype of BAV dis-
ease (ie,BAVstenosiswith concomitantmild tomoderate as-
cending aortic dilatation). The risk of adverse aortic events
may be higher in the subgroup of BAV patients with isolated
aortic valve insufficiency anddilatation of aortic root (ie, root
dilatation phenotype).20 This heterogeneity of the BAV pop-
ulation may explain the extraordinary high rate of aortic
events in some previously published follow-up studies.2
Progressive dilatation of the ascending aorta after isolated
AVR surgery in BAV patients compared with TAV patients
has been advocated in 1 previously published study.1However,
the conclusions in that reportwere based on retrospectively an-
alyzed data on 13BAVpatients versus 14 TAVpatients.More-
over, only 5 patients in the bicuspid subgroup had
a predominant BAV stenosis. Therefore, the findings of this
study may not be generalized to the entire BAV population.
In the current study, we found a comparably low risk of
adverse aortic events 15 years after isolated AVR in patients
with BAV versus TAV stenosis and concomitant mild to
moderate dilatation of the ascending aorta. No difference
was found in the prevalence of proximal aortic surgery be-
tween the study groups. Interestingly, 3 patients in the TAV
group underwent proximal aortic surgery for type A aortic
dissection. In contrast, no documented aortic dissection oc-
curred in the BAV group. These findings support our previ-
ous assumption that mildly to moderately dilated ascending
aorta in BAV stenosis behaves similar to the ascending aorta
of comparable dimensions in TAV stenosis during long-
term follow-up after isolated AVR surgery.
To the best of our knowledge, this is the first published re-
port that compares the risk of late aortic events after isolatedery c January 2014
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moderate dilatation of the ascending aorta. Andrus and asso-
ciates24 analyzed the natural course of ascending aortic an-
eurysms after isolated AVR by means of echocardiographic
follow-up.However, only half of their patients had a baseline
ascending aorta diameter35mm and only 13% had a con-
genital lesion of the aortic valve (ie, mono- and bicuspid
valves). Moreover, that study did not differentiate between
aortic valve stenosis and insufficiency. The authors found
no significant clinical or valvular characteristics that pre-
dicted progressive dilatation of the ascending aorta. More-
over, 2 additional studies analyzed the natural history of
ascending aortic aneurysms in the setting of unreplaced
BAV and compared them with the TAV population.25,26
Surprisingly, both of these studies demonstrated similar
rates of adverse aortic events in the BAV versus the TAV
groups. Moreover, the study by Davies and coworkers26
found a significant correlation between adverse aortic events
and the presence of relevant aortic stenosis.
In accordance with a previously published study,27 we
identified arterial hypertension as the only significant pre-
dictor of adverse aortic events after isolated AVR for aortic
valve stenosis. In particular, bicuspid valve pathology was
not a predictor of long-term aortic events.
We are aware of the fact, that the supracoronary ascend-
ing aortic replacement does not add much to AVR surgery
and does not really increase surgical risk in experienced
hands. Long-term benefit in terms of protection from prox-
imal aortic complications is obvious. However, this addi-
tional surgical maneuver may be associated with an
increased risk of bleeding events and transfusion require-
ments, especially in patients receiving anticoagulation/anti-
platelet medication. In addition, we have all seen rare but
dramatic complications from a supracoronary aortic
replacement. Moreover, the complexity of subsequent
redo surgery, which may be quite common in the relatively
young BAV population, may be significantly increased after
simultaneous aortic surgery. Nowadays, many isolated AVR
operations are performed using minimally invasive ap-
proaches, and the simultaneous proximal aortic surgery
may increase the complexity of such procedures. Last, we
believe that our data—in combination with several lines
of evidence from other studies suggesting a more benign
course for BAV aortopathy—is important to counter the
increasingly aggressive approach to BAV-associated aort-
opathy that has led some centers to replace such aortas
routinely starting at a diameter of 4.0 cm.
Study Limitations
The current study is a retrospective analysis with all
known limitations of such a study design. There are some
inherent age and comorbidity-related differences between
the study groups, which limit their comparability in part.
Patients with the degenerative TAV stenosis are generallyThe Journal of Thoracic and Caolder and sicker compared with the BAV population, result-
ing in decreased long-term survival and a higher prevalence
of late noncardiac deaths. Therefore, age-adjusted compar-
isons were performed using an analysis of covariance.
A proximal aortic diameter of 40 mm was our uniform
cutoff value for defining the dilatation of the aorta through-
out the years of the study. However, this is an arbitrary value
that may represent a limitation of our study.
Moreover, the relative aortic size compared with the aor-
tic isthmus was not available in the current study. We cor-
rected the proximal aortic size for body surface area only,
which was comparable between the study groups.
The use of a composite end point that includes elective
proximal aortic surgery may be potentially misleading, be-
cause it may be influenced by the personal experience and
the expertise of the surgical team toward the criteria of re-
placement of a dilated aorta. However, redo aortic surgery
is a major event during the postoperative course after
AVR, and it has been included in a combined end point
for the majority of prior follow-up studies.
Last, wewere not able to define the exact progression rate
of proximal aortic diameter in both study groups during
follow-up. Serial aortic imaging (ie, computed tomography
or magnetic resonance angiography) was available in only
65 of 320 patients (20%) in the study population. There-
fore, we decided not to include the aortic growth rate, based
on this small proportion of the study population. Given the
relatively modest progression rate of proximal aortic diam-
eter in patients who underwent redo aortic surgery (with the
only exception of 3 patients with aortic dissection) and the
low total number of adverse aortic events, it may be hypoth-
esized that the progression rate of proximal aortic dimen-
sions in the remaining study population was most
probably modest.
CONCLUSIONS
Our study demonstrates that patients with BAV versus
TAV stenosis and concomitant mild to moderate ascending
aortic dilatation are at comparably low risk of adverse aortic
events 15 years after isolated AVR. Based on these findings,
a conservative treatment strategy of the ascending aorta at
the time of AVR surgery in patients with aortic valve steno-
sis is warranted. However, caution should be advised when
one generalizes these results to patients with BAV insuffi-
ciency or other risk factors for aortic dilation. Moreover,
a thorough aortic imaging follow-up is required to deter-
mine the rate of aortic growth in patients with BAV versus
TAV stenosis and concomitant mild to moderate ascending
aortic dilatation after isolated AVR.
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